Add to ORKGGemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of th
Objective: The objectives of this study were to evaluate the efficacy and toxicity of combi-nation c...
BACKGROUND: This phase III trial compared the efficacy and safety of gemcitabine plus capecitabine (...
Abstract: Single agent gemcitabine has been the mainstay of therapy for advanced pancreatic cancer o...
Objective AIO-PK0104 investigated two treatment strategies in advanced pancreatic cancer (PC): a ref...
Despite advances in our understanding of the molecular and genetic basis of pancreatic cancer, the o...
PURPOSE: This phase III trial compared the efficacy and safety of gemcitabine (Gem) plus capecitabin...
PURPOSE: Treatment with gemcitabine provides modest benefits in patients with metastatic pancreatic ...
The purpose of this study is to retrospectively compare the efficacy and tolerability between three ...
See accompanying editorial on page 1621 Author affiliations appear at the end of this article. Publi...
Objective: Previous meta-analyses showed a survival advantage with gemcitabine (GEM)-based combinati...
Majority of the patients with pancreatic cancer present with advanced disease that is lethal and not...
PURPOSE: Both gemcitabine (GEM) and fluoropyrimidines are valuable treatment for advanced pancreatic...
This phase III trial compared the efficacy and safety of gemcitabine (Gem) plus capecitabine (GemCap...
Purpose Single-agent gemcitabine became standard first-line treatment for advanced pancreatic cancer...
Pancreatic adenocarcinoma is one of the most aggressive malignancies and the fourth leading cause of...
Objective: The objectives of this study were to evaluate the efficacy and toxicity of combi-nation c...
BACKGROUND: This phase III trial compared the efficacy and safety of gemcitabine plus capecitabine (...
Abstract: Single agent gemcitabine has been the mainstay of therapy for advanced pancreatic cancer o...
Objective AIO-PK0104 investigated two treatment strategies in advanced pancreatic cancer (PC): a ref...
Despite advances in our understanding of the molecular and genetic basis of pancreatic cancer, the o...
PURPOSE: This phase III trial compared the efficacy and safety of gemcitabine (Gem) plus capecitabin...
PURPOSE: Treatment with gemcitabine provides modest benefits in patients with metastatic pancreatic ...
The purpose of this study is to retrospectively compare the efficacy and tolerability between three ...
See accompanying editorial on page 1621 Author affiliations appear at the end of this article. Publi...
Objective: Previous meta-analyses showed a survival advantage with gemcitabine (GEM)-based combinati...
Majority of the patients with pancreatic cancer present with advanced disease that is lethal and not...
PURPOSE: Both gemcitabine (GEM) and fluoropyrimidines are valuable treatment for advanced pancreatic...
This phase III trial compared the efficacy and safety of gemcitabine (Gem) plus capecitabine (GemCap...
Purpose Single-agent gemcitabine became standard first-line treatment for advanced pancreatic cancer...
Pancreatic adenocarcinoma is one of the most aggressive malignancies and the fourth leading cause of...
Objective: The objectives of this study were to evaluate the efficacy and toxicity of combi-nation c...
BACKGROUND: This phase III trial compared the efficacy and safety of gemcitabine plus capecitabine (...
Abstract: Single agent gemcitabine has been the mainstay of therapy for advanced pancreatic cancer o...